Respiratory Medicine
Volume 104, Issue 4 , Pages 534-541, April 2010

Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis

  • Brigitta U. Monz

      Affiliations

    • Boehringer Ingelheim GmbH, Binger Strasse 173, D-55216 Ingelheim, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 6132 77 93362; fax: +49 6132 77 4233.
  • ,
  • Paul Sachs

      Affiliations

    • Stamford Hospital, Stamford, 190W. Broad Street, Stamford, CT 06902, United States
    • Columbia University College of Physicians and Surgeons, NY, United States
  • ,
  • Jeffrey McDonald

      Affiliations

    • Mapi Values, 133 Portland Street, Boston, MA 02114, United States
  • ,
  • Bruce Crawford

      Affiliations

    • Mapi Values, Arco Tower 8F, 1-8-1 Shimomeguro, Meguro-ku, Tokyo 153 0064, Japan
  • ,
  • Michael C. Nivens

      Affiliations

    • Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, United States
  • ,
  • Kay Tetzlaff

      Affiliations

    • Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT 06877, United States
    • Medical Clinic, Department of Sports Medicine, University of Tuebingen, Silcherstrasse 5, D-72076 Tuebingen, Germany

Received 24 November 2008; accepted 31 October 2009. published online 17 November 2009.

Summary 

Background

To assess the responsiveness of the Cough and Sputum Assessment Questionnaire (CASA-Q) in COPD and chronic bronchitis patients recovering from an acute exacerbation. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. The four domains (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels.

Methods

Outpatients were enrolled within 48h of symptom onset of their exacerbation. Treatment was initiated at the discretion of the investigator, and patients observed for 6 weeks. During study visits, 59 eligible patients completed the CASA-Q at enrolment, week 1, 2 and 6. Responsiveness was assessed by calculating standardized effect sizes.

Results

Of the 19 male and 40 female patients with a mean (standard deviation, SD) age of 61.1 (10.5) years, all were classified by their physician to have improved or recovered after six weeks. The mean (SD) CASA-Q sores for the cough symptom, cough impact, sputum symptom and sputum impact domains increased from 32.6 (21.0), 40.7 (22.4), 37.4 (20.1), 47.1 (24.2) at enrolment to 54.0 (19.8), 63.7 (21.3), 55.1 (19.0), 65.5 (20.5) at week 6, respectively. Standardized effect sizes for patients improved or recovered from their exacerbation at week 6 were above 1.0 for the cough domains and at least 0.77 for the sputum domains.

Conclusions

The CASA-Q was responsive to symptom changes in patients recovering from an exacerbation.

Keywords: Cough and sputum assessment questionnaire, COPD, Chronic bronchitis, Exacerbations, Responsiveness

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0954-6111(09)00361-8

doi:10.1016/j.rmed.2009.10.026

Respiratory Medicine
Volume 104, Issue 4 , Pages 534-541, April 2010